Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - EML Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the manufacturing, importation, advertising, and sale of therapeutic goods in Australia, ensuring they are of acceptable quality and pose minimal risk to health. This Act was introduced to address the need for comprehensive regulation of therapeutic goods to protect public health and safety. The enactment of this legislation aimed to establish a robust framework that governs the oversight of therapeutic goods, ensuring their safety, efficacy, and quality through licensing, monitoring, and enforcement mechanisms. The Therapeutic Goods Act 1989 is administered by the Therapeutic Goods Administration (TGA), which is part of the Australian Government's Department of Health. The policy objective of the Act is to safeguard public health by ensuring that therapeutic goods available in Australia meet necessary standards and are appropriately controlled.

Scope and Application

The Therapeutic Goods Act 1989 applies to a wide range of persons, entities, and conduct concerning the regulation of therapeutic goods in Australia, which includes medicines, medical devices, blood and blood components, tissues, and human cells. The Act applies to manufacturers, importers, sponsors, and suppliers of therapeutic goods, as well as to individuals and entities who advertise or claim to supply therapeutic goods. The Act's jurisdictional reach is national, as it is a Commonwealth Act, and it applies across all states and territories of Australia. The Act provides for the regulation of therapeutic goods from the point of manufacture to the point of consumer use, encompassing licensing, quality control, advertising, and labelling standards. The Act includes specific exclusions and exemptions, such as therapeutic goods used for personal use or research purposes, as well as thresholds for the level of regulatory oversight based on the risk profile of the goods. The application and enforcement of the Act may be extended or restricted through subordinate instruments such as regulations and guidelines, which provide further detail and operational direction on the implementation of the Act. In the case of the revoked licence, the manufacturer requested the revocation, and the Secretary exercised the power under the Act to revoke the licence accordingly.

Key Provisions

The Therapeutic Goods Act 1989 provides for the regulation of therapeutic goods, which include medicines, medical devices, blood and blood components, and tissues. Section 41(1)(d) of the Act allows the Secretary to revoke a manufacturer's licence under specific circumstances, such as at the request of the manufacturer themselves. In this instance, the Secretary has revoked the licence held by EML Pty Ltd, Licence No. MI-26112004-LI-000233-1, located at 427-431 Canterbury Road, Surrey Hills, VIC 3127, at the request of the manufacturer. Entities holding a licence to manufacture therapeutic goods under the Therapeutic Goods Act 1989 must comply with various obligations and requirements, including maintaining proper records, ensuring the quality and safety of the therapeutic goods produced, and adhering to any conditions or restrictions imposed by the Secretary on the licence. These entities must also report any adverse events or defects related to the therapeutic goods they manufacture. The revocation of a licence signifies that the manufacturer is no longer authorised to produce therapeutic goods under the terms of the Act. In cases where a licence is revoked, the manufacturer or the entity involved may face several consequences. While the Act does not explicitly detail offences, penalties, or consequences for a voluntary revocation, there could be implications for the manufacturer's reputation and ability to operate within the industry. Additionally, if the revocation was due to non-compliance or misconduct, the manufacturer might face further scrutiny, enforcement actions, or legal proceedings. It is essential for manufacturers to understand their obligations under the Therapeutic Goods Act 1989 to avoid potential penalties and maintain their licence.